Orchard Therapeutics announced the appointment of two gene therapy and industry experts, Fulvio Mavilio and Nicoletta Loggia to serve as chief scientific officer and chief technical officer, respectively. The company also announced the promotion of Leslie Meltzer who has been serving as senior vice president of medical affairs, clinical operations and diagnostics, to chief medical officer. Together, Drs. Mavilio, Loggia and Meltzer will oversee strategically important functions as Orchard continues to advance its later-stage portfolio and expand its hematopoietic stem cell (HSC) gene therapy pipeline into larger indications. Dr. Mavilio will lead the company’s discovery and translational research activities. In this capacity he will be responsible for expanding the company’s pipeline into larger indications. He joins Orchard Therapeutics from Smart Immune where he serves as chief scientific officer. Previously, Dr. Mavilio was senior vice president of translational science at Audentes Therapeutics in San Francisco. In her role, Dr. Loggia will be responsible for leading all aspects of technical operations, including process and analytical development, manufacturing, supply chain, engineering and CMC lifecycle management. She joins Orchard Therapeutics from Novartis, where she held positions of increasing responsibility since 2004, most recently serving as global head of cell and gene therapies.